Pre-made Lulizumab biosimilar ( Single Domain Variable Fragment;L, anti-CD28 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-326
Anti-CD28 therapeutic antibody (Pre-made Lulizumab biosimilar,Single Domain Variable Fragment;L) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases. This drug was developed by Bristol-Myers Squibb.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD28 therapeutic antibody (Pre-made Lulizumab biosimilar,Single Domain Variable Fragment;L)|
|Format||Single Domain Variable Fragment;L|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection|